Ken Griffin Lexaria Bioscience Corp. Transaction History

Citadel Advisors LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$1.29 - $6.25 $17,679 - $85,656	-13,705 Reduced 46.36%	15,856 $57,000
Q4 2023 Feb 14, 2024	BUY	$0.92 - $1.69 $27,196 - $49,958	29,561 New	29,561 $36,000
Q4 2022 Feb 14, 2023	SELL	$1.95 - $2.98 $12,090 - $18,476	-6,200 Reduced 24.93%	18,674 $45,000
Q3 2022 Nov 14, 2022	SELL	$0.74 - $3.28 $2,230 - $9,885	-3,014 Reduced 10.81%	24,874 $61,000

1.06M

Ticker LEXX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 5,951,000
Market Cap $13.7M
Description
Lexaria Bioscience Corp. operates as a biotechnology company. Its patented drug delivery technology, DehydraTECH, improves the way active pharmaceutical ingredients enter the bloodstream by promoting effective oral delivery. The company's DehydraTECH has demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.